It will provide billions for medical research and clears red tape so the Food and Drug Administration can approve drugs faster, something that could be good for drug companies. Most of Priceâ€™s trades were in the range of $1, 000 to $15, 000. His biggest position in 2016 was taken in an Australian biotech company called Innate Immunotherapeutic. Disclosure records indicate Price invested between $50, 000 and $100, 000 in the company that includes on its board of directors Rep. Chris Collins,   York. 